핵심 요약
- 1. The Canada Drug Agency recommended public funding for early-stage Alzheimer's patients to access the drug lecanemab.
- 2. The drug was rejected in February, but was approved following a reassessment requested by the manufacturer Eisai.
- 3. Conditions include that patients must have mild cognitive impairment and be monitored for brain swelling/bleeding with regular MRIs.
- 4. The annual cost of the drug is approximately 32,000 Canadian dollars, and it is administered intravenously every two or four weeks.
숫자로 보기
The Canada Drug Agency recommended that lecanemab, proven to slow the progression of early-stage Alzheimer's disease, be covered under public drug plans for patients meeting specific conditions. Although Health Canada approved the drug in October, the agency had previously recommended against public funding in February due to concerns about efficacy and potential side effects such as brain swelling or bleeding.
However, an expert committee that reassessed the situation at the request of the drug's manufacturer, Eisai, realized that it might have underestimated the clinical importance of the drug in its previous assessments. The agency acknowledged that early-stage Alzheimer's patients face a progressive and eventually debilitating condition with limited treatment options.
Eligible patients must have only mild cognitive impairment, have amyloid protein confirmed by a brain scan or cerebrospinal fluid analysis, and be monitored for signs of brain swelling or bleeding through regular MRIs. Alzheimer's associations in Canada have long been pushing for public funding for this drug, branded as Leqembi, which could give patients more quality time.
반응 남기기
이 기사에 대해 질문
답변은 이 기사만을 바탕으로 AI가 생성합니다.
자주 묻는 질문
- 1. Q: For which patients is lecanemab recommended?
- A: The drug is recommended only for early-stage Alzheimer's patients with mild cognitive impairment who have confirmed amyloid protein.
- 2. Q: Why did the Canada Drug Agency change its mind?
- A: Reassessing the situation at the request of the manufacturer, the agency stated that it might have initially underestimated the clinical importance of the drug and updated its recommendation.
- 3. Q: Under what circumstances will the use of the drug be discontinued?
- A: If the patient's condition progresses from mild dementia to moderate dementia, it is recommended that the drug no longer be covered, because the drug has only been proven effective in the early stage.